This site is intended for Healthcare Professionals only.

NHS England, ABPI, DHSC begin negotiation for new medicine pricing scheme


Share post:

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May).

A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023

In their first meeting, the government, NHS England and industry – represented by the ABPI –expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth.

Health Minister, Will Quince, said: “These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times – one of the Prime Minister’s 5 priorities.

The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

It’s vitally important that the successor to the current scheme delivers for the taxpayer, patients, the NHS, and life sciences.

Richard Torbett, Chief Executive at the ABPI, said: “These negotiations provide an opportunity to secure the UK’s place as a global leader in life science research and medical innovation while also ensuring the best outcomes for UK patients and a thriving economy.

Working together, we can boost UK science and create the conditions for innovative medicines to deliver their true value as an investment in the nation’s health, wealth, and productivity.

Sir Hugh Taylor, who chaired the Accelerated Access Review in 2014 to bring innovative technologies to the NHS, was appointed last month as Chief Negotiations Advisor for the VPAS scheme.

Sir Hugh Taylor, said: “The future voluntary scheme must continue to benefit the NHS and give its patients access to the best medicines, while supporting our life sciences sector.

I’m looking forward to reaching an agreement which not only benefits the NHS but will also encourage the pharmaceutical sector to continue investing in the UK.”



Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

Knights Pharmacy expands footprint in South Wales with acquisition of 2 new pharmacies

Knights pharmacy to provide independent prescribing services at the new locations in South Wales Knights Pharmacy has significantly expanded...

Pharmacy bodies respond to Labour Party manifesto promises on community pharmacy

Pharmacy leaders have urged funding boost for pharmacies in response to Labour's ambitious healthcare plans The Labour Party's election...

RPS calls on political leaders to end prescription charges for long-term conditions

RPS and PCC urge political leaders to urgently get rid of prescription charges for chronic conditions on the...

Corsodyl unveils new toothpaste and mouthwash range targeted at preventing gum problems

New Corsodyl Gum Strength & Protect line includes clinically proven formulas to enhance gum health and prevent issues With...